

Andrew Blauvelt

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3656879/andrew-blauvelt-publications-by-citations.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

275
papers

17,270
citations

62
h-index

125
g-index

365
ext. papers

20,900
ext. citations

5.6
avg. IF

6.73
L-index

#	Paper	IF	Citations
275	Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2016 , 375, 2335-2348	59.2	936
274	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017 , 389, 2287-2303	40	559
273	Human skin Langerhans cells are targets of dengue virus infection. <i>Nature Medicine</i> , 2000 , 6, 816-20	50.5	510
272	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2016 , 375, 345-56	59.2	505
271	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 403-417	4.5	476
270	IL-17 is essential for host defense against cutaneous <i>Staphylococcus aureus</i> infection in mice. <i>Journal of Clinical Investigation</i> , 2010 , 120, 1762-73	15.9	460
269	Circulating Th17, Th22, and Th1 cells are increased in psoriasis. <i>Journal of Investigative Dermatology</i> , 2010 , 130, 1373-83	4.3	439
268	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 400-9	4.5	380
267	Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2016 , 387, 40-52	40	360
266	Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. <i>Nature Medicine</i> , 1997 , 3, 1369-75	50.5	353
265	Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 2175-83	4.3	333
264	Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. <i>Science</i> , 2004 , 306, 485-7	33.3	329
263	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2017 , 376, 1551-1560	59.2	306
262	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. <i>Lancet, The</i> , 2017 , 390, 276-288	40	302
261	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2016 , 175, 273-86	4	297
260	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. <i>Lancet, The</i> , 2018 , 392, 650-661	40	283
259	Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. <i>Current Rheumatology Reports</i> , 2007 , 9, 461-7	4.9	276

258	Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). <i>British Journal of Dermatology</i> , 2015 , 172, 484-93	4	230
257	The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. <i>Clinical Reviews in Allergy and Immunology</i> , 2018 , 55, 379-390	12.3	228
256	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 83-98.e4	4.5	212
255	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 60-69.e9	4.5	210
254	Quantifying the harmful effect of psoriasis on health-related quality of life. <i>Journal of the American Academy of Dermatology</i> , 2002 , 47, 512-8	4.5	207
253	Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. <i>Journal of Clinical Investigation</i> , 2004 , 113, 701-708	15.9	204
252	Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. <i>Blood</i> , 2001 , 97, 3244-50	2.2	191
251	IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. <i>Journal of Immunology</i> , 2011 , 186, 1495-502	5.3	181
250	IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against <i>Candida albicans</i> . <i>Journal of Immunology</i> , 2010 , 185, 5453-62	5.3	179
249	Visualization of human herpesvirus type 8 in Kaposi sarcoma by light and transmission electron microscopy. <i>Aids</i> , 1997 , 11, F35-45	3.5	176
248	Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. <i>Journal of Virology</i> , 2003 , 77, 1021-38	6.6	171
247	Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways. <i>Journal of Clinical Investigation</i> , 1997 , 100, 2043-53	15.9	162
246	R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 8401-6	11.5	161
245	Conjunctivitis in dupilumab clinical trials. <i>British Journal of Dermatology</i> , 2019 , 181, 459-473	4	147
244	Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2020 , 156, 44-56	5.1	146
243	Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. <i>Arthritis Research and Therapy</i> , 2019 , 21, 111	5.7	144
242	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. <i>Lancet, The</i> , 2019 , 394, 831-839	4.0	141
241	Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. <i>European Journal of Immunology</i> , 1999 , 29, 2551-9	6.1	141

240	Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. <i>Journal of Experimental Medicine</i> , 2000 , 192, 1491-500	16.6	139
239	Consensus guidelines for the management of plaque psoriasis. <i>Archives of Dermatology</i> , 2012 , 148, 95-102		135
238	Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. <i>Drugs</i> , 2018 , 78, 463-478	12.1	123
237	Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. <i>Journal of Immunology</i> , 1995 , 154, 4851-6	5.3	120
236	Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2020 , 156, 411-420	5.1	118
235	T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 1064-7	4.3	114
234	Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6. <i>Journal of Investigative Dermatology</i> , 2002 , 119, 793-7	4.3	111
233	From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 168-77	4.5	107
232	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 277-286.e10	4.5	105
231	Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 506-515	4.5	104
230	Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 81-89.e5	4.5	95
229	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 302-314.e6	4.5	94
228	A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 1176-82	4.5	87
227	Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 1058-69	4.5	87
226	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 266-276.e5	4.5	86
225	Interleukin-15 mRNA is expressed by human keratinocytes Langerhans cells, and blood-derived dendritic cells and is downregulated by ultraviolet B radiation. <i>Journal of Investigative Dermatology</i> , 1996 , 106, 1047-52	4.3	86
224	Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). <i>British Journal of Dermatology</i> , 2021 , 184, 437-449	4	84
223	Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 855-862	4.5	80

222	Efalizumab for severe atopic dermatitis: a pilot study in adults. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 222-7	4.5	80
221	Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. <i>British Journal of Dermatology</i> , 2018 , 179, 623-631	4	78
220	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 377-388	4.5	77
219	Safety of secukinumab in the treatment of psoriasis. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1413-20	4.1	75
218	Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. <i>Journal of Virology</i> , 2003 , 77, 6188-96	6.6	74
217	Human herpesvirus 8 infection occurs following adolescence in the United States. <i>Journal of Infectious Diseases</i> , 1997 , 176, 771-4	7	70
216	Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells. <i>Journal of Immunology</i> , 2003 , 170, 4260-6	5.3	66
215	Clinical meaningfulness of complete skin clearance in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 77-82.e7	4.5	65
214	Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease. <i>Journal of Investigative Dermatology</i> , 2002 , 119, 365-9	4.3	63
213	Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2020 , 156, 649-658	5.1	62
212	PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. <i>Journal of Virology</i> , 2004 , 78, 7602-9	6.6	60
211	Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. <i>British Journal of Dermatology</i> , 2018 , 179, 844-852	4	59
210	Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. <i>British Journal of Dermatology</i> , 2020 , 182, 605-617	4	59
209	Human Langerhans cells express E-cadherin. <i>Journal of Investigative Dermatology</i> , 1995 , 104, 293-6	4.3	58
208	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. <i>British Journal of Dermatology</i> , 2020 , 182, 1348-1358	4	58
207	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). <i>British Journal of Dermatology</i> , 2018 , 178, 674-681	4	57
206	The role of Langerhans cells in the sexual transmission of HIV. <i>Journal of Dermatological Science</i> , 2005 , 40, 147-55	4.3	57
205	Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 158-167.e1	4.5	57

204	Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. <i>JAMA Dermatology</i> , 2018 , 154, 676-683	5.1	56
203	Gram-positive bacteria enhance HIV-1 susceptibility in Langerhans cells, but not in dendritic cells, via Toll-like receptor activation. <i>Blood</i> , 2009 , 113, 5157-66	2.2	56
202	HIV-infected Langerhans cells preferentially transmit virus to proliferating autologous CD4+ memory T cells located within Langerhans cell-T cell clusters. <i>Journal of Immunology</i> , 2004 , 172, 2219-24	5.3	55
201	Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. <i>Lancet, The</i> , 2021 , 397, 2151-2168	4.0	55
200	11. Allergic and immunologic diseases of the skin. <i>Journal of Allergy and Clinical Immunology</i> , 2003 , 111, S560-70	11.5	54
199	Functional studies of epidermal Langerhans cells and blood monocytes in HIV-infected persons. <i>Journal of Immunology</i> , 1995 , 154, 3506-15	5.3	52
198	Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. <i>Archives of Dermatology</i> , 2002 , 138, 1341-6		51
197	Identification and rapid quantification of early- and late-lytic human herpesvirus 8 infection in single cells by flow cytometric analysis: characterization of antihherpesvirus agents. <i>Journal of Virology</i> , 1999 , 73, 5894-902	6.6	51
196	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 487-498	4.0	51
195	IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 1946-1953	4.3	50
194	Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. <i>British Journal of Dermatology</i> , 2021 , 184, 50-59	4	50
193	Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus. <i>Blood</i> , 2001 , 97, 2374-80	2.2	48
192	Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2021 , 157, 1047-1055	5.1	48
191	Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. <i>Journal of Immunology</i> , 1999 , 163, 1666-73	5.3	48
190	Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, 533-40	4.5	47
189	The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 642-50	4.5	46
188	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 117-122	4.5	46
187	Pityriasis rubra pilaris and HIV infection. <i>Journal of the American Academy of Dermatology</i> , 1991 , 24, 703-5	4.5	44

186	Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 475-486	4.0	44
185	Antimicrobial peptide LL-37 produced by HSV-2-infected keratinocytes enhances HIV infection of Langerhans cells. <i>Cell Host and Microbe</i> , 2013 , 13, 77-86	23.4	43
184	Significant virus replication in Langerhans cells following application of HIV to abraded skin: relevance to occupational transmission of HIV. <i>Journal of Immunology</i> , 2008 , 180, 3297-304	5.3	43
183	Porphyria cutanea tarda and human immunodeficiency virus infection. <i>International Journal of Dermatology</i> , 1992 , 31, 474-9	1.7	43
182	New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF- β . <i>Expert Review of Dermatology</i> , 2007 , 2, 69-78		42
181	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1254-1268	4.5	42
180	Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). <i>British Journal of Dermatology</i> , 2020 , 182, 1120-1135	4	42
179	Cytokines regulate expression and function of the HIV coreceptor CXCR4 on human mature dendritic cells. <i>Journal of Immunology</i> , 1998 , 161, 3219-23	5.3	42
178	Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1004-1013	14.6	40
177	Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. <i>British Journal of Dermatology</i> , 2018 , 178, 132-139	4	40
176	Low levels of productive HIV infection in Langerhans cell-like dendritic cells differentiated in the presence of TGF- β 1 and increased viral replication with CD40 ligand-induced maturation. <i>European Journal of Immunology</i> , 2001 , 31, 360-8	6.1	40
175	Basal cell carcinoma of the scrotum. Report of three cases and review of the literature. <i>Journal of the American Academy of Dermatology</i> , 1992 , 26, 574-8	4.5	40
174	Phosphorylation of the invariant chain by protein kinase C regulates MHC class II trafficking to antigen-processing compartments. <i>Journal of Immunology</i> , 1999 , 163, 5435-43	5.3	40
173	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018 , 179, 615-622	4	39
172	HIV-infected human Langerhans cells transmit infection to human lymphoid tissue ex vivo. <i>Aids</i> , 2000 , 14, 647-51	3.5	38
171	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 936-945	4.5	38
170	Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results). <i>Dermatology and Therapy</i> , 2018 , 8, 571-579	4	38
169	Bimekizumab versus Secukinumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021 , 385, 142-152	5.2	38

168	Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. <i>British Journal of Dermatology</i> , 2017 , 177, 1495-1502	4	37
167	Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 1173-81	4.3	37
166	UVB induces IL-12 transcription in human keratinocytes in vivo and in vitro. <i>Photochemistry and Photobiology</i> , 1996 , 63, 854-9	3.6	37
165	Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials. <i>Journal of Drugs in Dermatology</i> , 2015 , 14, 821-33	2.2	37
164	A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). <i>Journal of Investigative Dermatology</i> , 2020 , 140, 1784-1793.e2	4.3	36
163	Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P). <i>British Journal of Dermatology</i> , 2018 , 178, 1315-1323	4	36
162	Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2017 , 176, 752-758	4	36
161	Stromal-derived factor 1 expression in the human thymus. <i>Journal of Immunology</i> , 2002 , 168, 2609-17	5.3	35
160	Widespread primary cutaneous infection with <i>Mycobacterium fortuitum</i> . <i>International Journal of Dermatology</i> , 1993 , 32, 512-4	1.7	35
159	Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 567-577	7.1	34
158	Human herpesvirus 6 infects dendritic cells and suppresses human immunodeficiency virus type 1 replication in coinfecting cultures. <i>Journal of Virology</i> , 1999 , 73, 4019-28	6.6	34
157	Lymphatic dysfunction in transgenic mice expressing KSHV k-cyclin under the control of the VEGFR-3 promoter. <i>Blood</i> , 2005 , 105, 2356-63	2.2	33
156	Long-term radiographic follow-up after isotretinoin therapy. <i>Journal of the American Academy of Dermatology</i> , 1988 , 18, 1252-61	4.5	33
155	Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR). <i>British Journal of Dermatology</i> , 2017 , 177, 1552-1561	4	32
154	Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 372-374	4.5	32
153	Oncostatin M enhances CCL21 expression by microvascular endothelial cells and increases the efficiency of dendritic cell trafficking to lymph nodes. <i>Journal of Immunology</i> , 2006 , 177, 7665-72	5.3	32
152	An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. <i>Blood</i> , 2000 , 96, 2562-7	2.2	32
151	Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2017 , 177, 1537-1551	4	31

150	Modulation of T cell responses to recall antigens presented by Langerhans cells in HIV-discordant identical twins by anti-interleukin (IL)-10 antibodies and IL-12. <i>Journal of Clinical Investigation</i> , 1996 , 97, 1550-5	15.9	31
149	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1704-1716	4.5	31
148	Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation. <i>Oncotarget</i> , 2015 , 6, 18081-93	3.3	30
147	Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. <i>British Journal of Dermatology</i> , 2016 , 174, 282-6	4	30
146	HIV-Dendritic cell interactions promote efficient viral infection of T cells. <i>Journal of Biomedical Science</i> , 1998 , 5, 253-9	13.3	29
145	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020 , 10, 133-150	4	29
144	Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. <i>New England Journal of Medicine</i> , 2021 , 384, 512-520	59.2	29
143	Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1367-1374	4.5	28
142	Skin diseases associated with human herpesvirus 6, 7, and 8 infection. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2001 , 6, 197-202	1.1	28
141	Bimekizumab versus Adalimumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021 , 385, 130-140	59.2	28
140	Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1483-1490	4.6	27
139	No evidence of human herpesvirus 8 infection in patients with paraneoplastic pemphigus, pemphigus vulgaris, or pemphigus foliaceus. <i>Journal of Investigative Dermatology</i> , 1998 , 111, 781-3	4.3	27
138	Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). <i>American Journal of Clinical Dermatology</i> , 2017 , 18, 273-280	7.1	26
137	Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. <i>RMD Open</i> , 2019 , 5, e000942	5.9	26
136	Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. <i>Journal of Drugs in Dermatology</i> , 2018 , 17, 826-832	2.2	26
135	Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial. <i>Journal of Investigative Dermatology</i> , 2018 , 138, 1973-1981	4.3	25
134	Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 927-935	4.5	25
133	Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1138-1149	4.5	25

132	Variant genotypes of FcγRIIIA influence the development of Kaposi's sarcoma in HIV-infected men. <i>Blood</i> , 2000 , 95, 2386-90	2.2	25
131	Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox. <i>Dermatologic Clinics</i> , 2003 , 21, 301-9	4.2	24
130	Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 119-131	7.1	24
129	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. <i>British Journal of Dermatology</i> , 2021 , 184, 1047-1058	4	24
128	IL-6 Differs from TNF- α Unpredicted Clinical Effects Caused by IL-6 Blockade in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 541-542	4.3	23
127	A Clinician's Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2016 , 17, 329-36	7.1	23
126	Inflammatory skin disease in K5.hTGF- β 1 transgenic mice is not dependent on the IL-23/Th17 inflammatory pathway. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 2443-50	4.3	23
125	HIV-related eosinophilic folliculitis: a panel discussion. <i>Seminars in Cutaneous Medicine and Surgery</i> , 1997 , 16, 219-23	1.4	23
124	Orf-induced immunobullous disease: A distinct autoimmune blistering disorder. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 49-55	4.5	23
123	Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 546-552	4.6	22
122	Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis. <i>Journal of Investigative Dermatology</i> , 2018 , 138, 2168-2173	4.3	22
121	Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2015 , 8, 563-9	2.9	21
120	Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302). <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 869-877	4.5	21
119	Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2017 , 177, 879-881	4	19
118	Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 863-871	7.1	19
117	Delayed wound healing due to increased interleukin-10 expression in mice with lymphatic dysfunction. <i>Journal of Leukocyte Biology</i> , 2013 , 94, 137-45	6.5	19
116	Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 741-748	4.5	18
115	Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial. <i>Journal of Drugs in Dermatology</i> , 2016 , 15, 1226-1234	2.3	18

114	Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 255-63	5.4	17
113	C34, a membrane fusion inhibitor, blocks HIV infection of langerhans cells and viral transmission to T cells. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 1436-43	4.3	17
112	The future of academic dermatology in the United States: report on the resident retreat for future physician-scientists, June 15-17, 2001. <i>Journal of the American Academy of Dermatology</i> , 2002 , 47, 300-3	4.5	17
111	Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. <i>Journal of Drugs in Dermatology</i> , 2013 , 12, 874-80	2.2	17
110	Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 294-301.e6	4.5	16
109	Lymphatic dysfunction impairs antigen-specific immunization, but augments tissue swelling following contact with allergens. <i>Journal of Investigative Dermatology</i> , 2012 , 132, 667-76	4.3	16
108	Propagation of a human herpesvirus from AIDS-associated Kaposi sarcoma. <i>New England Journal of Medicine</i> , 1997 , 336, 1837-9	59.2	16
107	Detection with the polymerase chain reaction of human papillomavirus DNA in condylomata acuminata treated in vitro with liquid nitrogen, trichloroacetic acid, and podophyllin. <i>Journal of the American Academy of Dermatology</i> , 1992 , 26, 710-4	4.5	16
106	Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 1707-1718.e9	4.3	16
105	Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. <i>British Journal of Dermatology</i> , 2019 , 180, 306-314	4	16
104	Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab. <i>Patient Preference and Adherence</i> , 2020 , 14, 517-527	2.4	15
103	Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 2305-2312	4.6	15
102	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2013 , 6, S2-S20	1.2	15
101	Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 135-142	4.6	15
100	Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1098-1106	4.6	14
99	Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. <i>British Journal of Dermatology</i> , 2019 , 181, 196-197	4	14
98	Minimal reactivation of Kaposi sarcoma-associated herpesvirus by corticosteroids in latently infected B cell lines. <i>Journal of Medical Virology</i> , 2002 , 66, 378-83	19.7	14
97	Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. <i>British Journal of Dermatology</i> , 2020 , 182, 1359-1368	4	14

96	Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. <i>British Journal of Dermatology</i> , 2020 , 182, 180-189	4	14
95	A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail. <i>British Journal of Dermatology</i> , 2021 , 184, 270-280	4	14
94	Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1733-1741	4.6	12
93	Biosimilars for psoriasis: clinical studies to determine similarity. <i>British Journal of Dermatology</i> , 2017 , 177, 23-33	4	12
92	The Skin as Target, Vector, and Effector Organ in Human Immunodeficiency Virus Disease. <i>Journal of Investigative Dermatology</i> , 1995 , 105, S122-S126	4.3	12
91	Human papillomavirus type 6 infection involving cutaneous nongenital sites. <i>Journal of the American Academy of Dermatology</i> , 1992 , 27, 876-9	4.5	12
90	Cutaneous cryptococcosis mimicking Kaposi's sarcoma as the initial manifestation of disseminated disease. <i>International Journal of Dermatology</i> , 1992 , 31, 279-80	1.7	12
89	Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials. <i>Journal of Drugs in Dermatology</i> , 2018 , 17, 200-206	2.2	12
88	Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1693-1699	4.6	11
87	A novel, short, and simple screening questionnaire can suggest presence of psoriatic arthritis in psoriasis patients in a dermatology clinic. <i>Clinical Rheumatology</i> , 2015 , 34, 1745-51	3.9	11
86	Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. <i>Journal of Dermatological Treatment</i> , 2020 , 1-9	2.8	11
85	Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019 , 25, 1366-1376	1.9	11
84	Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 360-368	4.5	10
83	Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1515-1522	4.6	10
82	Developing drugs for treatment of atopic dermatitis in children (8 months to . <i>Pediatric Dermatology</i> , 2018 , 35, 303-322	1.9	10
81	Sequelae of World War II: an outbreak of chronic cutaneous nontuberculous mycobacterial infection among Satowanese islanders. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1541-6	11.6	10
80	Morphogenesis of HHV8 in primary human dermal microvascular endothelium and primary effusion lymphomas. <i>Ultrastructural Pathology</i> , 2000 , 24, 291-300	1.3	10
79	Idiopathic and L-tryptophan-associated eosinophilic fasciitis before and after L-tryptophan contamination. <i>Archives of Dermatology</i> , 1991 , 127, 1159-66		10

78	Tyrosine kinase 2 and Janus kinase-signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	10
77	Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis. <i>Journal of Drugs in Dermatology</i> , 2015 , 14, 805-12	2.2	10
76	Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 1405-1409	4.5	9
75	Histone deacetylase inhibitors induce apoptosis with minimal viral reactivation in cells infected with Kaposi's sarcoma-associated herpesvirus. <i>Journal of Investigative Dermatology</i> , 2006 , 126, 2516-24	4.3	9
74	Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. <i>British Journal of Dermatology</i> , 2021 , 184, 640-651	4	9
73	Dupilumab Improves Patient-Reported Outcomes (PROs) in a Phase 2 Study in Adults with Moderate-to-Severe Atopic Dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 135, AB167	11.5	8
72	A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 1513-1515	4.3	8
71	Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials. <i>British Journal of Dermatology</i> , 2020 , 182, 880-888	4	8
70	Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV ex vivo infection of Langerhans cells within the epithelium. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 2803-2805	4.3	7
69	Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	7
68	Dupilumab Improves Asthma and Sinusitis Outcomes in Adults with Moderate to Severe Atopic Dermatitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 1212-1223.e6	5.4	7
67	Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). <i>British Journal of Dermatology</i> , 2021 , 184, 652-662	4	7
66	Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. <i>American Journal of Clinical Dermatology</i> , 2021 , 22, 101-115	7.1	7
65	Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. <i>British Journal of Dermatology</i> , 2017 , 177, 587-590	4	6
64	Blocking MAPK signaling downregulates CCL21 in lymphatic endothelial cells and impairs contact hypersensitivity responses. <i>Journal of Investigative Dermatology</i> , 2011 , 131, 1927-35	4.3	6
63	Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 220-229	2.8	6
62	Widespread cutaneous vascular papules associated with peripheral blood eosinophilia and prominent inguinal lymphadenopathy. <i>Journal of the American Academy of Dermatology</i> , 2000 , 43, 698-700	4.5	5
61	Bimekizumab for the Treatment of Psoriasis. <i>Drugs</i> , 2021 , 81, 1751-1762	12.1	5

60	Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 141-146	2.8	5
59	Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes. <i>Journal of Drugs in Dermatology</i> , 2020 , 19, 487-492	2.2	4
58	Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2021 ,	4	4
57	Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials. <i>Journal of the American Association of Nurse Practitioners</i> , 2018 , 30, 529-541	1	4
56	New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 2328-2337	4.3	4
55	Hepatitis C virus and human immunodeficiency virus infection can alter porphyrin metabolism and lead to porphyria cutanea tarda. <i>Archives of Dermatology</i> , 1996 , 132, 1503-4		4
54	Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis. <i>Journal of Drugs in Dermatology</i> , 2019 , 18, 297-299	2.2	4
53	Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).. <i>American Journal of Clinical Dermatology</i> , 2022 , 1	7.1	4
52	Dual Inhibition of IL-12/IL-23 and Selective Inhibition of IL-23 in Psoriasis 2018 , 123-131		3
51	Papillary thyroid carcinoma in a patient with severe psoriasis receiving adalimumab. <i>Journal of the American Academy of Dermatology</i> , 2011 , 64, 999-1000	4.5	3
50	Gianotti-Crosti syndrome and human immunodeficiency virus infection. <i>Archives of Dermatology</i> , 1994 , 130, 481-3		3
49	Eosinophilic folliculitis associated with the acquired immunodeficiency syndrome responds well to permethrin. <i>Archives of Dermatology</i> , 1995 , 131, 360-1		3
48	Identification of Mycobacterium tuberculosis DNA in five different types of cutaneous lesions by the polymerase chain reaction. <i>Archives of Dermatology</i> , 1993 , 129, 1594-8		3
47	Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2). <i>SKIN the Journal of Cutaneous Medicine</i> , 2020 , 4, s96	2.6	3
46	Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 417-421	4.6	3
45	Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE). <i>SKIN the Journal of Cutaneous Medicine</i> , 2021 , 5, s15	2.6	3
44	Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.. <i>Dermatology and Therapy</i> , 2022 , 12, 727	4	3
43	Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis. <i>British Journal of Dermatology</i> , 2020 , 182, e186-e209	4	2

42	Bimekizumab. <i>Current Dermatology Reports</i> , 2020 , 9, 36-42	1.5	2
41	Ixekizumab—An Effective and Safe Treatment for Moderate-to-Severe Plaque Psoriasis in Patients Previously Treated With Other IL-17 Inhibitors: Results From IXORA-P. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019 , 4, 180-185	1.1	2
40	398 Efficacy and safety of ixekizumab for the treatment of plaque psoriasis: Results through 108 weeks randomised, phase III clinical trial (UNCOVER-3). <i>Journal of Investigative Dermatology</i> , 2017 , 137, S260	4.3	2
39	Implications for biologic therapy: Staphylococcus aureus decolonization of individuals with a history of recurrent skin and soft-tissue infections. <i>JAMA Dermatology</i> , 2013 , 149, 986-9	5.1	2
38	In This Issue—Full Court Press on Psoriasis. <i>Journal of Investigative Dermatology</i> , 2004 , 123, vii-viii	4.3	2
37	Human papillomavirus DNA in the dermis of condyloma acuminatum. <i>Journal of Cutaneous Pathology</i> , 1993 , 20, 447-50	1.7	2
36	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016 , 9, S5-S29	1.2	2
35	Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study. <i>SKIN the Journal of Cutaneous Medicine</i> , 2020 , 4, s82	2.6	2
34	Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal. <i>SKIN the Journal of Cutaneous Medicine</i> , 2020 , 4, s83	2.6	2
33	Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS). <i>BioDrugs</i> , 2021 , 35, 229-238	7.9	2
32	Concerns and perceptions of patients with psoriatic disease during the COVID-19 pandemic: results from a two-wave survey by the National Psoriasis Foundation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e354-e355	4.6	2
31	Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 84-94	1.9	2
30	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , 2021 , 1-8	2.8	2
29	Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes. <i>Journal of Drugs in Dermatology</i> , 2020 , 19, 487-492	2.2	2
28	Predicting Clinical Responses to Ustekinumab: Progress Toward a Future of Personalized Medicine. <i>JAMA Dermatology</i> , 2019 , 155, 1227-1228	5.1	1
27	Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks. <i>Dermatology and Therapy</i> , 2021 , 12, 223	4	1
26	Defining drug-free remission of skin disease in patients with plaque psoriasis. <i>British Journal of Dermatology</i> , 2020 , 182, 1484-1487	4	1
25	Reply to: Do interleukin 17 inhibitors increase risk of respiratory tract infections?. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, e303-e304	4.5	1

24	Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2021 , 1-9	2.8	1
23	Response to critical appraisal of LIBERTY AD CHRONOS. <i>British Journal of Dermatology</i> , 2018 , 179, 1423-4	4	1
22	Authors' Reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes". <i>Drugs</i> , 2018 , 78, 853-855	12.1	1
21	Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2398-2408	4.6	1
20	Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months. <i>Dermatology and Therapy</i> , 2021 , 11, 2133-2145	4	0
19	Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial. <i>Dermatology and Therapy</i> , 2020 , 10, 1415-1421	4	0
18	Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index. <i>ACR Open Rheumatology</i> , 2021 , 3, 501-511	3.5	0
17	Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: data from a national US survey. <i>British Journal of Dermatology</i> , 2021 ,	4	0
16	A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17. <i>Dermatology and Therapy</i> , 2022 , 12, 787	4	0
15	A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab. <i>Dermatology and Therapy</i> , 2022 , 12, 701	4	0
14	Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment. <i>Dermatology and Therapy</i> , 2021 , 12, 195	4	0
13	Kaposi's sarcoma and human dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus express CCL21. <i>Journal of Dermatological Science</i> , 2011 , 61, 139-42	4.3	
12	Treatment of Psoriasis in the Setting of Excessive Alcohol Intake: From the Medical Board of the National Psoriasis Foundation. <i>Psoriasis Forum</i> , 2011 , 17a, 119-130		
11	Cutaneous diseases 473-502		
10	Cutaneous diseases 2005 , 413-430		
9	Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year. <i>Dermatology and Therapy</i> , 2022 , 12, 9-13	4	
8	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2014 , 7, S5-S22	1.2	
7	Efficacité et tolérance du bimekizumab chez des patients présentant un psoriasis en plaques modérément sévère: résultats de BE VIVID, une étude de phase 3 de 52 semaines, randomisée, en double aveugle, contrôlée versus ustkinumab et versus placebo. <i>Annales De Dermatologie Et De Venereologie</i> , 2020 , 117, A359-A360	0.3	

6	COVID-19 and Psoriasis: New Guidance From the NPF. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020 , 5, 127-128	1.1
5	How to Best Define Psoriasis Severity: A New Consensus Statement From the International Psoriasis Council. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021 , 6, 6-7	1.1
4	An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e828-e831	4.6
3	A boxed warning for inadequate psoriasis treatment. <i>Cutis</i> , 2016 , 98, 206-207	0.4
2	Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.. <i>Dermatology and Therapy</i> , 2022 , 12, 911	4
1	Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over two years of follow-up in real-world settings. <i>Journal of Medical Economics</i> , 1-44	2.4